How Many Uniqure NV (NASDAQ:QURE)’s Analysts Are Bearish?

July 18, 2017 - By Michael Collier

 How Many Uniqure NV (NASDAQ:QURE)'s Analysts Are Bearish?

Uniqure NV (NASDAQ:QURE) Ratings Coverage

Among 12 analysts covering uniQure N.V. (NASDAQ:QURE), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. uniQure N.V. has $60 highest and $8 lowest target. $33.20’s average target is 412.35% above currents $6.48 stock price. uniQure N.V. had 23 analyst reports since August 7, 2015 according to SRatingsIntel. On Friday, August 28 the stock rating was maintained by WallachBeth Capital with “Buy”. The firm has “Buy” rating by Janney Capital given on Tuesday, December 1. The rating was reinitiated by H.C. Wainwright with “Buy” on Wednesday, February 24. WallachBeth Capital maintained it with “Buy” rating and $60 target in Tuesday, December 1 report. The company was maintained on Thursday, August 27 by Chardan Capital Markets. The firm earned “Hold” rating on Tuesday, November 22 by Jefferies. Oppenheimer maintained it with “Buy” rating and $1700 target in Wednesday, June 28 report. The company was downgraded on Tuesday, September 1 by Zacks. The rating was maintained by Oppenheimer on Monday, September 21 with “Outperform”. The rating was reinitiated by H.C. Wainwright on Thursday, August 4 with “Buy”. Below is a list of Uniqure NV (NASDAQ:QURE) latest ratings and price target changes.

12/07/2017 Broker: Cowen & Co Rating: Buy Maintain
28/06/2017 Broker: Oppenheimer Rating: Buy New Target: $17.0000 Maintain

The stock decreased 0.15% or $0.01 during the last trading session, reaching $6.48. About shares traded. Uniqure NV (NASDAQ:QURE) has declined 52.65% since July 18, 2016 and is downtrending. It has underperformed by 69.35% the S&P500.

Uniqure NV is a gene therapy company based in the Netherlands. The company has market cap of $161.84 million. The Firm is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. It currently has negative earnings. The Firm advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

More news for Uniqure NV (NASDAQ:QURE) were recently published by:, which released: “uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating …” on July 11, 2017.‘s article titled: “uniQure (QURE) Reports Presentations at ISTH” and published on June 23, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.